Jun 27, 2023 8:30am EDT Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
Jun 26, 2023 8:30am EDT Artelo Biosciences Reports Superior Preclinical Pharmaceutical Properties and Efficacy of ART12.11 Compared to Cannabidiol (CBD) at the 33rd Annual International Cannabinoid Research Society Symposium
Jun 07, 2023 8:30am EDT Artelo Biosciences Selected for Oral Presentation to Report Positive Research Findings on ART12.11 at the 33rd Annual International Cannabinoid Research Society Symposium
May 11, 2023 8:00am EDT Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
Apr 25, 2023 8:30am EDT Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Mar 31, 2023 8:00am EDT Artelo Biosciences Reports Fiscal 2022 Year-End Financial Results and Provides Business Update
Feb 15, 2023 8:30am EST Artelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023
Feb 02, 2023 9:00am EST Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Jan 26, 2023 8:30am EST Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
Nov 08, 2022 8:00am EST Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
